Published in Ann Oncol on July 19, 2010
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol (2014) 1.05
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol (2012) 0.88
Major clinical research advances in gynecologic cancer in 2010. J Gynecol Oncol (2010) 0.85
Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Invest New Drugs (2011) 0.77
Trabectedin in ovarian cancer: could we expect more? Ann Oncol (2010) 0.75
Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence. Onco Targets Ther (2014) 0.75
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol (2009) 3.72
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol (2010) 3.33
Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer (1989) 2.43
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology (2007) 1.70
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol (2005) 1.41
Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol (2006) 1.31
Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs (2007) 1.24
Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol (2006) 1.21
Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol (2003) 1.12
Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist (1999) 1.09
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer (2007) 1.05
Role of gemcitabine in ovarian cancer treatment. Ann Oncol (2006) 1.03
Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol (1995) 1.02
Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer (2009) 1.00
Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer (2005) 1.00
Unique features of the mode of action of ET-743. Oncologist (2002) 0.97
The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol (2004) 0.94
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol (2009) 0.94
Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma. Drugs Today (Barc) (2009) 0.90
Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol (2003) 0.89
Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. Int J Gynecol Cancer (2008) 0.88
Trabectedin: an anticancer drug from the sea. Expert Opin Pharmacother (2009) 0.88
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Br J Cancer (2009) 0.88
Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med (1989) 10.60
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (2003) 8.88
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol (2000) 6.06
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A (2001) 5.57
A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A (1992) 4.77
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med (1995) 4.75
Publication bias and clinical trials. Control Clin Trials (1987) 4.34
Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet (2000) 3.44
Condylomatous lesions of the cervix. II. Cytologic, colposcopic and histopathologic study. Acta Cytol (1977) 3.36
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol (2000) 3.33
Gene expression profiling of cells, tissues, and developmental stages of the nematode C. elegans. Cold Spring Harb Symp Quant Biol (2003) 3.22
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 2.98
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol (2002) 2.86
Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med (1988) 2.85
Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol (2000) 2.70
CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice. J Exp Med (1995) 2.70
Cardiotocography only versus cardiotocography plus ST analysis of fetal electrocardiogram for intrapartum fetal monitoring: a Swedish randomised controlled trial. Lancet (2001) 2.68
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Risk factors for suicide completion in major depression: a case-control study of impulsive and aggressive behaviors in men. Am J Psychiatry (2005) 2.54
A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A (1996) 2.52
Eukaryotic translation initiation factor 4GI is a cellular target for NS1 protein, a translational activator of influenza virus. Mol Cell Biol (2000) 2.48
Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell (2001) 2.43
Randomized trial of periportal peritoneal bupivacaine for pain relief after laparoscopic cholecystectomy. Br J Surg (1996) 2.33
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst (1996) 2.30
The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol Cell (1999) 2.25
The influence of age on apoptotic and other mechanisms of cell death after cerebral hypoxia-ischemia. Cell Death Differ (2005) 2.22
Focal cortical dysplasia: neuropathological subtypes, EEG, neuroimaging and surgical outcome. Brain (2002) 2.17
The natural history of CADASIL: a pooled analysis of previously published cases. Stroke (1999) 2.14
Role of diaphragmatic surgery in 69 patients with ovarian carcinoma. Int J Gynecol Cancer (2008) 2.12
Nucleotide sequence of two rasH related-genes isolated from the yeast Saccharomyces cerevisiae. Nucleic Acids Res (1984) 2.10
Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology (2004) 2.09
Factors related to the development of CMV-specific CD8+ T cell response in CMV-seropositive solid organ transplant candidates. Am J Transplant (2015) 2.08
Umbilical cord blood banks in the UK. BMJ (2001) 2.08
Individual expression of influenza virus PA protein induces degradation of coexpressed proteins. J Virol (1995) 2.02
[Identification of gaps in the clinical patient care of asthma in Spain. Results of the OPTIMA-GEMA survey]. An Sist Sanit Navar (2016) 2.02
Bacterial endotoxin sensitizes the immature brain to hypoxic--ischaemic injury. Eur J Neurosci (2001) 2.02
Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol (2002) 2.00
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst (2000) 1.99
Quantification of growth factor levels using a simplified method of platelet-rich plasma gel preparation. J Oral Maxillofac Surg (2000) 1.99
PA subunit from influenza virus polymerase complex interacts with a cellular protein with homology to a family of transcriptional activators. J Virol (2001) 1.98
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol (1994) 1.97
HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer (2011) 1.95
Monoclonal antibodies against influenza virus PB2 and NP polypeptides interfere with the initiation step of viral mRNA synthesis in vitro. J Virol (1994) 1.93
Cerebral palsy and restricted growth status at birth: population-based case-control study. BJOG (2008) 1.90
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer (1995) 1.88
Allergy testing in children: why, who, when and how? Allergy (2003) 1.86
Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol (2008) 1.86
Lymph node metastases in low-grade endometrial stromal sarcoma. Gynecol Oncol (2005) 1.83
Synthesis of biologically active influenza virus core proteins using a vaccinia virus-T7 RNA polymerase expression system. J Gen Virol (1994) 1.83
Influence of age and hemodynamics on myocardial blood flow and flow reserve. Circulation (1993) 1.81
The amino-terminal one-third of the influenza virus PA protein is responsible for the induction of proteolysis. J Virol (1996) 1.79
Hypocaloric total parenteral nutrition: effectiveness in prevention of hyperglycemia and infectious complications--a randomized clinical trial. Crit Care Med (2000) 1.79
International consensus on (ICON) pediatric asthma. Allergy (2012) 1.79
Synergistic activation of caspase-3 by m-calpain after neonatal hypoxia-ischemia: a mechanism of "pathological apoptosis"? J Biol Chem (2000) 1.77
Effect of exercise level on the ability of thallium-201 tomographic imaging in detecting coronary artery disease: analysis of 461 patients. J Am Coll Cardiol (1989) 1.77
Apoptosis-inducing factor is a major contributor to neuronal loss induced by neonatal cerebral hypoxia-ischemia. Cell Death Differ (2006) 1.77
A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. J Clin Pathol (1997) 1.76
Inactivation of phosphofructokinase by glucagon in rat hepatocytes. J Biol Chem (1979) 1.76
A novel mechanism of PKA anchoring revealed by solution structures of anchoring complexes. EMBO J (2001) 1.75
The molecular basis for protein kinase A anchoring revealed by solution NMR. Nat Struct Biol (1999) 1.74
Electroclinical, MRI and neuropathological study of 10 patients with nodular heterotopia, with surgical outcomes. Brain (2004) 1.73
Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J (1996) 1.71
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
Symptoms in 18,495 Persian Gulf War veterans. Latency of onset and lack of association with self-reported exposures. J Occup Environ Med (1998) 1.69
The replication activity of influenza virus polymerase is linked to the capacity of the PA subunit to induce proteolysis. J Virol (2000) 1.69
Homozygous familial hypercholesterolemia among French Canadians in Québec Province. Arteriosclerosis (1989) 1.68
A reference cross DNA panel for zebrafish (Danio rerio) anchored with simple sequence length polymorphisms. Development (1996) 1.67
Genetic homogeneity at the Friedreich ataxia locus on chromosome 9. Am J Hum Genet (1989) 1.66
Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med (1999) 1.65
Influenza virus infection causes specific degradation of the largest subunit of cellular RNA polymerase II. J Virol (2007) 1.64
Alpha-2b interferon and oral clodronate for Gorham's disease. Lancet (1998) 1.63
Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology (2007) 1.63
Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer (2003) 1.61
Direct measurement of antibody affinity distribution by hapten-inhibition enzyme immunoassay. Mol Immunol (1984) 1.61
A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health (2007) 1.61
c-myc oncogene expression in colorectal cancer. Cancer (1987) 1.60
Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol (2000) 1.60
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) Ann Oncol (1998) 1.60
Spontaneous and induced mutations in a single open reading frame alter both virulence and avirulence in Xanthomonas campestris pv. vesicatoria avrBs2. J Bacteriol (1996) 1.58
An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS (1998) 1.57
Codon 178 mutation in ethnically diverse Creutzfeldt-Jakob disease families. Lancet (1991) 1.56
Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol (1994) 1.56
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst (2010) 1.55
A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol (1996) 1.54
Maternal complications and perinatal mortality: findings of the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG (2014) 1.54
Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. Ann Oncol (2005) 1.54
miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene (2012) 1.54
EORTC-GCG process quality indicators for ovarian cancer surgery. Eur J Cancer (2008) 1.53
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol (2007) 1.52